coagulation factor VIIa(redirected from NovoSeven RT)
coagulation factor VIIa (recombinant)
Pharmacologic class: Coagulation factor VIIa
Therapeutic class: Antihemophilic agent
Pregnancy risk category C
FDA Box Warning
• Arterial and venous thrombotic and thromboembolic events following administration of NovoSeven RT have been reported during postmarketing surveillance. Clinical studies have shown an increased risk of arterial thromboembolic adverse events with NovoSeven RT when administered outside the current approved indications. Fatal and nonfatal thrombotic events have been reported.
• Discuss the risks and explain the signs and symptoms of thrombotic and thromboembolic events to patients who will receive NovoSeven RT.
• Monitor patients for signs or symptoms of activation of the coagulation system and for thrombosis.
• Safety and efficacy of NovoSeven RT haven't been established outside the approved indications.
Promotes hemostasis by activating intrinsic pathway of coagulation cascade to form fibrin
Lyophilized powder for injection: 1 mg/vial, 2 mg/vial, 5 mg/vial
Indications and dosages
➣ Bleeding episodes in patients with hemophilia A or B who have inhibitors to factor VIII or IX and in patients with acquired hemophilia
Adults: For hemostatic dosing, 90 mcg/kg I.V. bolus q 2 hours until hemostasis occurs or therapy is deemed ineffective. For posthemostatic dosing, appropriate dosing duration hasn't been determined. For severe bleeds, continue dosing at 3- to 6-hour intervals after hemostasis is achieved, to maintain hemostatic plug.
➣ Prevention of bleeding in surgical interventions or invasive procedures in patients with hemophilia A or B who have inhibitors to factor VIII or IX and in patients with acquired hemophilia
Adults: Initially, 90 mcg/kg I.V. immediately before intervention and repeated at 2-hour intervals for duration of surgery. For minor surgery, administer postsurgical doses by I.V. bolus injection at 2-hour intervals for first 48 hours and then at 2- to 6-hour intervals until healing has occurred. For major surgery, administer postsurgical doses by I.V. injection at 2-hour intervals for 5 days, followed by 4-hour intervals until healing has occurred. Administer additional bolus doses, if required.
➣ Bleeding episodes or prevention of bleeding in surgical intervention or invasive procedures in patients with congenital factor VII deficiency
Adults: 15 to 30 mcg/kg I.V. q 4 to 6 hours until hemostasis is achieved. Effective treatment has been achieved with dosages as low as 10 mcg/kg.
➣ Bleeding episodes or surgery in patients with acquired hemophilia
Adults: 70 to 90 mcg/kg I.V., repeated q 2 to 3 hours until hemostasis is achieved
Use cautiously in:
• hypersensitivity to drug, its components, or mouse, hamster, or bovine products
• prolonged use of drug
• concomitant use of activated or non-activated prothrombin complex concentrates (avoid use)
• patients with increased risk of thromboembolic complications (including advanced atherosclerotic disease, crush injury, septicemia, history of coronary heart disease, liver disease, disseminated intravascular coagulation, postoperative immobilization, elderly patients and neonates)
• pregnant or breastfeeding patients
• Monitor factor VII-deficient patients for prothrombin time and factor VII coagulant activity before administering drug.
☞ Give by I.V. bolus only over 2 to 5 minutes, depending on dosage.
• Reconstitute only with specified volume of diluent supplied.
☞ Don't mix with sterile water for injection or infusion solutions.
☞ Don't inject diluent directly on the powder.
• Administer within 3 hours of reconstituting. If line needs to be flushed before or after administering drug, use normal saline solution.
cerebral artery occlusion, cerebrovascular accident
CV: hypertension, hypotension, bradycardia, angina, superficial thrombophlebitis, thrombophlebitis, deep vein thrombosis, coagulation disorder, disseminated intravascular coagulation (DIC), increased fibrinolysis, purpura
GI: nausea, vomiting
GU: renal dysfunction
Hematologic: purpura, hemorrhage, hemarthrosis, disseminated intravascular coagulation, coagulation disorders, decreased fibrinogen plasma, thrombosis
Musculoskeletal: arthrosis, arthralgia
Respiratory: pneumonia, pulmonary embolism
Skin: pruritus, rash, urticaria
Other: fever, edema, pain, redness or reaction at injection site, hypersensitivity reaction
Drug-drug. Activated prothrombin complex concentrates, prothrombin complex concentrates: risk of potential interaction (though not evaluated)
☞ Monitor for signs and symptoms of coagulation activation or thrombosis. If DIC or thrombosis is confirmed, reduce dosage or discontinue drug, depending on patient's symptoms.
• Monitor factor VII-deficient patients for prothrombin time and factor VII coagulant activity before and after administering drug. If factor VIIa activity fails to reach expected level, prothrombin time isn't corrected, or bleeding isn't controlled after treatment with recommended dosages, antibody formation may be suspected and analysis for antibodies should be performed.
• Be aware that laboratory coagulation parameters may be used as adjunct to clinical evaluation of hemostasis to monitor drug efficacy and treatment schedule. However, these parameters lack direct correlation with achievement of hemostasis.
• Monitor renal function tests.
☞ Instruct patient to immediately report signs and symptoms of hypersensitivity reactions (including hives, urticaria, chest tightness, or wheezing) and thrombosis (including new-onset swelling and pain in limbs or abdomen, new-onset chest pain, shortness of breath, loss of sensation, or altered consciousness or speech).
• Instruct patient to report swelling, pain, burning, or itching at infusion site.
• Tell patient to inform prescriber if she's pregnant or intends to become pregnant.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs mentioned above.